Biogen flags sixth case of PML

Biogen Idec reported a sixth case of the potentially fatal brain disease progressive multifocal leukoencephalopathy, or PML, in a multiple sclerosis patient taking its drug Tysabri. According to Dow Jones, about 40,000 patients were using Tysabri at the end of the first quarter, and 24,900 of them have used the drug for a year or more. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.